Sandoz Says All Options Still Open After Spinoff Rumors
Unconfirmed Report Suggested Novartis Was Favoring Separate Listing Over Sale
Executive Summary
Sandoz has responded to recent rumors that parent company Novartis is favoring a spinoff of the generics and biosimilars business over a sale or retention, insisting that “all options remain open” as a strategic review of the unit continues.
You may also be interested in...
Generics Bulletin Explains: Sandoz’s Spinoff From Novartis
Ahead of a Sandoz capital markets day on 8 June, Generics Bulletin explains what we know so far about the firm’s spinoff from parent company Novartis – as well as the questions that the companies are yet to answer.
Sandoz Set To Become Public Company In 2023 As Novartis Confirms Spin-Off
Following years of dedicated moves towards greater autonomy for Sandoz, the generics and biosimilars giant is to become a publicly traded, standalone firm via a 100% spin-off from parent Novartis. However, a substantial offer could still derail plans.
The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations
A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.